Secugen S.L. started in 2005 as a spin-out company of the Biological Research Centre (CIB-CSIC) to exploit DNA sequencing in the biomedicine and biotechnology fields. The company’s main research interest is improving genetic analysis and molecular diagnostics using state of the art DNA sequencing platforms. Secugen has developed methods for the sequencing and annotation of several human genes and has generated strategies for the mutation screening of complex gene-sets implicated in human diseases like dementia, age related macular degeneration and atypical haemolytic uremic syndrome. In particular, Secugen staff has a solid expertise in the analysis of human complement genes including, CFH, CFI, MCP, CFB, DAF, Properdin and C3.